Compare NSA & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSA | SLNO |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | 1458 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | N/A | 2014 |
| Metric | NSA | SLNO |
|---|---|---|
| Price | $42.92 | $53.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $34.38 | ★ $83.00 |
| AVG Volume (30 Days) | 721.5K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.59 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | N/A | $150.46 |
| Revenue Next Year | $2.39 | $50.37 |
| P/E Ratio | ★ $56.31 | $89.83 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $27.43 | $29.43 |
| 52 Week High | $44.02 | $89.12 |
| Indicator | NSA | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 77.32 |
| Support Level | $40.89 | $48.91 |
| Resistance Level | $43.96 | $55.47 |
| Average True Range (ATR) | 0.84 | 0.05 |
| MACD | -0.06 | -0.52 |
| Stochastic Oscillator | 68.64 | 100.00 |
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.